Program 4 (Volastra Therapeutics)

Program 4 is a preclinical-stage drug development program being advanced by Volastra Therapeutics. As of current pipeline disclosures, the specific biological target, therapeutic modality, and primary disease indications for this program remain undisclosed. The program is part of Volastra's broader research and development efforts focused on chromosomal instability (CIN), a hallmark of many solid tumors. Volastra utilizes its proprietary CINsight engine to identify and validate targets that are synthetically lethal in the context of high chromosomal instability, aiming to develop novel cancer therapies that overcome resistance and progression.